Nirsevimab provides age-specific protection against RSV hospitalisation in the first year of life: a population-level study in Queensland, Australia
Communicable Diseases Intelligence · 2026
DOI: 10.33321/cdi.2026.50.066 ↗Kurz gefasst
Fachartikel in der Zeitschrift Communicable Diseases Intelligence, 2026. Verfasst von Asmaa El-Heneidy und 5 weiteren Autor:innen. Beteiligte Einrichtung: Griffith Biostatistics Unit, Griffith University, Gold Coast QLD 4215, Australia; School of Medicine and Dentistry, Griffith University, Gold Coast, …. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Hospitalization, Antiviral Agents. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Nirsevimab, a long-acting monoclonal antibody with activity against respiratory syncytial virus (RSV), was introduced into the Queensland paediatric RSV prevention program in 2024. Using Queensland Notifiable Conditions Register (NoCS) data, we found that the infant cohort eligible for the nirsevimab program had lower RSV hospitalisation rates than comparable pre-program cohorts. The population-level impact of nirsevimab was greatest during the first month of life (incidence rate ratio [IRR]: 0.22; 95% confidence interval [95% CI]: 0.16–0.31; representing a 78% reduction in hospitalisation rate), with its magnitude gradually declining thereafter until nine months of age (IRR: 0.77; 95% CI: 0.62–0.96; a 23% reduction), following which the impact of nirsevimab on hospitalisation rate, with increasing age of the infant or child, was no longer statistically significant. An interrupted time-series analysis demonstrated an immediate 63% reduction in RSV hospitalisations following nirsevimab’s introduction (IRR: 0.37; 95% CI: 0.23–0.60), showing a substantial population-level impact of the program in Queensland, Australia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Griffith Biostatistics Unit, Griffith University, Gold Coast QLD 4215, Australia; School of Medicine and Dentistry, Griffith University, Gold Coast, QLD 4215, Australia. a.el-heneidy@griffith.edu.au.
- School of Medicine and Dentistry, Griffith University, Gold Coast, QLD 4215, Australia.
- Public Health Intelligence Branch, Queensland Health, Brisbane QLD 4006, Australia.
- Child Health Research Centre, The University of Queensland, South Brisbane, QLD 4101, Australia; National Centre for Immunisation Research and Surveillance, Westmead, NSW 2145, Australia.
- Griffith Biostatistics Unit, Griffith University, Gold Coast QLD 4215, Australia; School of Medicine and Dentistry, Griffith University, Gold Coast, QLD 4215, Australia; Wesley Research Institute, Brisbane QLD 4066, Aus…
Zitieren
APA
El-Heneidy, A., Grimwood, K., Rajmokan, M., Shrestha, A., Lambert, S., & Ware, R. (2026). Nirsevimab provides age-specific protection against RSV hospitalisation in the first year of life: a population-level study in Queensland, Australia. Communicable Diseases Intelligence. https://doi.org/10.33321/cdi.2026.50.066
Vancouver
El-Heneidy A, Grimwood K, Rajmokan M, Shrestha A, Lambert S, Ware R. Nirsevimab provides age-specific protection against RSV hospitalisation in the first year of life: a population-level study in Queensland, Australia. Communicable Diseases Intelligence. 2026. doi:10.33321/cdi.2026.50.066
BibTeX
@article{ElHeneidy2026,
author = {El-Heneidy, Asmaa and Grimwood, Keith and Rajmokan, Mohana and Shrestha, Ashish and Lambert, Stephen and Ware, Robert},
title = {Nirsevimab provides age-specific protection against RSV hospitalisation in the first year of life: a population-level study in Queensland, Australia},
journal = {Communicable Diseases Intelligence},
year = {2026},
doi = {10.33321/cdi.2026.50.066}
}
EUVIMED